AACR 2022 poster. Using solid tumor analytical validation of T-regulatory immunohistochemistry multiplex for clinical studies
Our Histoprofile®- T-reg light panel is ready for use in your clinical trials
Our in-depth analytical validation ensures the quality of this robust protocol on solid tumor tissues. Evaluate T-cell subpopulations and their spatial distribution in the tumor microenvironment.
Amanda Finan
The Complexity of Myeloid-Derived Suppressor Cells in Non-small Cell Lung Cancer: A Combinatorial Multiplex IHC and Flow Cytometry Approach
In Situ Multiplex Analysis of Regulatory and Effector T Cells in Multiple Tumor Types
In Situ Multiplex Analysis of Resident Microglia and Infiltrating Macrophages in Glioblastoma
Multiplex Immunofluorescence Detection of Resident Memory T Cells in Solid Tumors
Assessing Clinical Response in Multiple Myeloma Patients Treated with Monoclonal Antibodies
Immune Cell Checkpoint Profiling of Solid Tumors
Immune checkpoint proteins are important regulators in self-tolerance but also allow cancer cells to evade immune destruction. Checkpoint inhibitor (CKI) blockade therapies can help restore antitumoral immunity. Combination blockade has demonstrated the potential to result in greater tumor growth inhibition than monotherapies in preclinical studies. Multiplex immunofluorescence offers a technical advantage by allowing for the detection of co-expression and spatial organization of multiple targets within a preserved tissue architecture on a single slide. We have developed the HISTOPROFILE®-CKI multiplex immunohistochemistry panel to offer personalized immune cell checkpoint profiling.